Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Newport Beach, California 92663


Purpose:

RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have stage IV or recurrent melanoma.


Study summary:

OBJECTIVES: - Determine the safety of immunization with autologous in vitro-treated tumor cells and dendritic cells in combination with sargramostim (GM-CSF) in patients with stage IV or recurrent melanoma. - Determine the frequency of conversion of delayed tumor hypersensitivity tests in patients treated with this regimen. - Determine the progression-free and overall survival in patients treated with this regimen. - Determine the objective tumor response rate in patients with measurable melanoma treated with this regimen. OUTLINE: Patients are stratified according to presence of measurable disease at study initiation (yes vs no). Patients undergo tumor cell harvest. Patients with multiple persistent sites of metastatic disease after harvest may receive systemic therapy (biologic therapy and/or chemotherapy) during tumor cell line expansion over approximately 4 months. The tumor cell line is expanded, irradiated, and treated with interferon gamma. Patients undergo leukapheresis to collect peripheral blood mononuclear cells (PBMC) to obtain dendritic cells (DC). The PBMC are treated with sargramostim (GM-CSF) and interleukin-4 for 7 days to produce DC. The DC are then cultured with the treated tumor cells for 18 hours. Patients undergo delayed tumor hypersensitivity tests intradermally 1 week prior to vaccination and again at week 4. Patients receive vaccine therapy comprising autologous treated tumor cells and dendritic cells suspended in GM-CSF subcutaneously weekly for 3 weeks. Vaccine therapy continues monthly for an additional 5 months in the absence of disease progression or unacceptable toxicity. Patients are followed every 2 months for 1 year and then every 3 months for 4 years. PROJECTED ACCRUAL: A total of 30-80 patients will be accrued for this study.


Criteria:

DISEASE CHARACTERISTICS: - Histologically confirmed stage IV or recurrent melanoma - Metastatic disease confirmed by MRI or CT scan - Planned resection of tumor - No active CNS metastases - Radiographically confirmed lack of CNS disease progression - No requirement for pharmacologic doses of corticosteroids PATIENT CHARACTERISTICS: Age: - Over 16 Performance status: - ECOG 0-2 Life expectancy: - At least 4 months Hematopoietic: - Hematocrit greater than 25% - Platelet count greater than 100,000/mm^3 - No ongoing transfusion requirements - No active blood clotting or bleeding diathesis Hepatic: - Bilirubin no greater than 2.0 mg/dL - Albumin at least 3.0 g/dL Renal: - Creatinine no greater than 2.0 mg/dL Cardiovascular: - No underlying cardiac disease associated with known myocardial dysfunction - No unstable angina related to atherosclerotic cardiovascular disease Other: - No other malignancy within the past 5 years except for carcinoma in situ, basal cell carcinoma, or localized squamous cell skin cancer - No active, eminently life-threatening infection or medical condition - Adequate venous access - Not pregnant - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - Other prior putative vaccines allowed - Recovered from prior biologic therapy - No other concurrent biologic therapy except epoetin alfa for patients with hematocrit less than 36% Chemotherapy: - At least 3 weeks since prior chemotherapy and recovered - No concurrent chemotherapy Endocrine therapy: - See Disease Characteristics - No concurrent endocrine therapy Radiotherapy: - At least 3 weeks since prior radiotherapy (including whole brain radiotherapy) and recovered - No concurrent radiotherapy Surgery: - See Disease Characteristics - Recovered from prior surgery Other: - Concurrent bisphosphonates allowed for patients with lytic bone metastases - No concurrent digoxin or other medications designed to improve cardiac output - No other concurrent investigational therapy


NCT ID:

NCT00012064


Primary Contact:

Study Chair
Robert O. Dillman, MD, FACP
Hoag Memorial Hospital Presbyterian


Backup Contact:

N/A


Location Contact:

Newport Beach, California 92663
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: September 20, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.